A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
NCT ID: NCT06877702
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
85 participants
INTERVENTIONAL
2025-03-19
2025-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects
NCT02790125
A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants
NCT04082741
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants
NCT06086886
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants
NCT05760937
An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
NCT03634995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Sequence 1
BMS-986460
Specified dose on specified days.
Part 1: Sequence 2
BMS-986460
Specified dose on specified days.
Part 1: Sequence 3
BMS-986460
Specified dose on specified days.
Part 2: Treatment A
BMS-986460
Specified dose on specified days.
Part 2: Treatment B
BMS-986460
Specified dose on specified days.
Part 2: Optional Treatment C
BMS-986460
Specified dose on specified days.
Part 2: Optional Treatment D
BMS-986460
Specified dose on specified days.
Part 2: Optional Treatment E
BMS-986460
Specified dose on specified days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986460
Specified dose on specified days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have a Body mass index (BMI) between 18.0 and 35.0 kilograms/meter square (kg/m2), inclusive.
* Male participants who are sexually active with individuals of childbearing potential (IOCBP) must agree to follow instructions for methods of contraception.
Exclusion Criteria
* Participants with left ventricular ejection fraction (≤ 50%) at screening are excluded.
* Participants with history of anaphylactic reactions are excluded.
* Participants with current or recent (within 3 months of intervention administration) gastrointestinal disease that, in the opinion of the investigator, could affect the absorption of study intervention are excluded.
* Participants with history of Gilbert's syndrome are excluded.
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0001
Lenexa, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA125-1018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.